MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31, BCAX had -$393,026K decrease in cash & cash equivalents over the period. -$107,114K in free cash flow.

Cash Flow Overview

Change in Cash
-$393,026K
Free Cash flow
-$107,114K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from issuance on common...
    • Stock-based compensation
    • Accounts payable and accrued exp...
    • Others
Negative Cash Flow Breakdown
    • Purchases of marketable securiti...
    • Operating lease liabilities
    • Purchase of property and equipme...

Cash Flow
2025-12-31
Net loss
-137,950
Stock-based compensation
15,006
Depreciation
105
Non-cash lease expense
895
Net amortization of premiums and discounts on marketable securities
-301
Prepaid expenses and other assets
-5,281
Accounts payable and accrued expenses-Nonrelated Party
7,657
Accounts payable and accrued expenses-Related Party
2,803
Operating lease liabilities
-932
Net cash used in operating activities
-106,834
Purchases of marketable securities
318,173
Purchase of property and equipment
280
Proceeds from sale of property and equipment
0
Net cash used in investing activities
-318,453
Proceeds from issuance on common stock, net of issuance costs
29,498
Proceeds from exercise of options
2,763
Net cash provided by financing activities
32,261
Net increase (decrease) in cash and cash equivalents
-393,026
Cash and cash equivalents at beginning of period
489,711
Cash and cash equivalents at end of period
96,685
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

Proceeds from issuance oncommon stock, net of...$29,498K Proceeds from exercise ofoptions$2,763K Net cash provided byfinancing activities$32,261K Net increase(decrease) in cash and cash...-$393,026K Canceled cashflow$32,261K Stock-based compensation$15,006K Accounts payable andaccrued...$7,657K Prepaid expenses andother assets-$5,281K Accounts payable andaccrued...$2,803K Non-cash lease expense$895K Net amortization ofpremiums and discounts on...-$301K Depreciation$105K Net cash used ininvesting activities-$318,453K Net cash used inoperating activities-$106,834K Canceled cashflow$32,048K Purchases of marketablesecurities$318,173K Purchase of property andequipment$280K Net loss-$137,950K Operating leaseliabilities-$932K

Bicara Therapeutics Inc. (BCAX)

Bicara Therapeutics Inc. (BCAX)